Patents by Inventor Joyce Behrens

Joyce Behrens has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20120004129
    Abstract: The invention relates to a method for assessing the effect of integrin inhibitors and small molecule ATP site directed multi kinase inhibitors on angiogenesis by the use of certain identified biomarkers. This method is notably beneficial for the determination of the efficacy of integrin inhibitors and small molecule ATP site directed multi-kinase inhibitors mainly used for the treatment of angiogenesis associated diseases such as cancer. Especially, the invention relates to biomarkers linked to angiogenesis that are preferably accessible in body fluids and therefore allow analysis of target modulation in a non-invasive way. The use of said biomarkers for the screening of compounds with integrin-inhibitory activity is also disclosed.
    Type: Application
    Filed: December 14, 2009
    Publication date: January 5, 2012
    Inventor: Joyce Behrens
  • Publication number: 20110244506
    Abstract: The invention relates to diagnosis and therapy of tumors utilizing the epidermal growth factor (EGFR) by means of chemical inhibitors or monoclonal antibodies. The invention relates also to skin irritations, preferably skin rash, in conjunction and associated with the treatment of tumor cells that utilize EGF receptor with anti-cancer agents. The invention is also directed to methods of predicting the efficiency of a tumor therapy/tumor response in a patient based on the treatment with EGFR inhibitors, especially anti-EGFR antibodies. The invention further relates to a method of determining the optimum dose of an anti-cancer agent in EGFR related tumor therapy.
    Type: Application
    Filed: January 7, 2011
    Publication date: October 6, 2011
    Applicant: Merck Patent GmbH
    Inventors: Arne Sutter, Joyce Behrens
  • Publication number: 20080199850
    Abstract: The invention relates to diagnosis and therapy of tumors utilizinging the epidermal growth factor (EGFR) by means of chemical inhibitors or monoclonal antibodies. The invention relates also to skin irritations, preferably skin rash, in conjunction and associated with the treatment of tumor cells that utilize EGF receptor with anti-cancer agents. The invention is also directed to methods of predicting the efficiency of a tumor therapy/tumor response in a patient based on the treatment with EGFR inhibitors, especially anti-EGFR antibodies. The invention further relates to a method of determining the optimum dose of an anti-cancer agent in EGFR related tumor therapy.
    Type: Application
    Filed: October 11, 2006
    Publication date: August 21, 2008
    Applicant: Merck Patent GmbH
    Inventors: Arne Sutter, Joyce Behrens